New York, New York, USA
Fraqtal • Gilgamesh Pharmaceutical • Optosom • Pfizer • Seelos • ONE Integration • Perception Neuroscience • The Center for Optimal Living • Horizons • Evolver • Pharmacology & Therapeutics • Ketamind • Noah Potter Law • Vicente Sederberg • KCSA • Mattio Communications • Four Sigmatic • NYU Langone Health • Columbia University • Icahn School of Medicine at Mount Sinai • Weill Medical College of Cornell University • Gabrielle's Angel Foundation • American Foundation for Suicide Prevention • Neurogene Inc. • The Ketamine Research Foundation • Brain & Behavior Research Foundation • Bronx Veterans Medical Research Foundation, Inc • New York City Health and Hospitals Corporation • New York State Psychiatric Institute • New York Presbyterian Hospital • The Brooklyn Hospital Center • Hospital for Special Surgery, New York • Target Health Inc. • Roivant Sciences, Inc. • National Multiple Sclerosis Society • THRiVE • Memorial Sloan Kettering Cancer Center • Forest Laboratories • Zuber Lawler • Heally • AIkido Pharma • Frequency • Drug Policy Alliance • People of Color Psychedelic Collective • Relmada Therapeutics • NY Ketamine Infusions • Columbia Psychiatry • Floresta Retreat • Hudson Mind • Trent & Company
Tabula Rasa Ventures • 14W • Able Partners • Innovating Capital • Michael Novogratz • New Enterprise Associates (NEA) • Presight Capital • Psilos Group • Subversive Capital • Republic Labs • Energia • General Catalyst • Decheng Capital • JLS Fund • Falcon Edge Capital • Pura Vida Investments • Highline Capital • WPSS • Negev Capital • Mont Alo Capital • BTG Capital • Gaingels • integrated • BAR Capital
Marik Hazan • Alex Zubillaga • Ryan Ackell • Lisa Blau • Alison Ryu • Amanda Eilian • Eric Chen • Andrew Amarosa • Michael Novogratz • Crystal Huang • Tony Florence • Tina He • Fabian Hansen • Patrick Farrell • Joseph Riley • David Eichler • Guy Levy • Steve Musumeci • Greg Dryer • Copter Ruangrojanin • Jay Campbell • Peter Molloy • Peter McDonough • Everett Ware • Peter Di Iorio • Aly Beynon • Dr. Aimée Derbes, LAc, DACM • Noël Graupner • Ashley Sobel • Zach Lomis • John Andreadis • Philip Taub • Daniel Love • Eugene Shteyngarts • Nancy Trent • Anand Shahi
Chief Financial Officer (m/f/d) • Finance Manager (m/f/d) • Nurse Practitioner • Psychotherapist • FP&A Manager | R&D Finance • Group Controller • Legal Counsel (Corporate) • VP FP&A • VP Human Resources/People • Psychiatric Mental Health Nurse Practitioner • Executive Assistant • DevOps Engineer • Public Relations Manager • Unsolicited application • Director of IT and Enterprise Applications • Software Engineering and IT Project Manager • Data Scientist • Machine Learning Scientist • Training Programme Lead • Legal compliance analyst / paralegal • Project Manager, Drug Discovery Center, 2 year contract position, with potential for extension • Licensed Psychotherapist • Launch Editor, Psychedelics • Remote Psychedelics Nurse Practitioner • Impact Manager • FrontEnd Engineer - Psychedelic Wellness App - Freelance [Remote]
A Study of Psilocybin for Major Depressive Disorder (MDD) • The Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Religious Professionals • The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression • Psilocybin Cancer Anxiety Study • A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence • Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD • A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1) • A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD • The Role of HNKs in the Antidepressant Effect of Ketamine • Intravenous Ketamine in the Treatment of Obsessive-Compulsive Disorder • Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD) • Ketamine in the Treatment of Depression • Low-Dose Ketamine in Children With ADNP Syndrome • Ketamine in the Treatment of Suicidal Depression • Ketamine for Suicidality in Bipolar Depression • Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With OCD • Ketamine and Nitroprusside for Depression • A Comparison of Intra-op Ketamine vs Placebo in Patients Having Spinal Fusion • Investigation of the NMDA Antagonist Ketamine as a Treatment for Tinnitus • Extending Ketamine's Effects in OCD With Exposure and Response Prevention (EX/RP) • Continuation Ketamine in Major Depression • Randomized Controlled Trial of Ketamine Infusion With Continuous Epidural Infusion for Treatment of Complex Regional Pain Syndrome • Effect of Ketamine on Laboratory-induced Stress in Healthy Subjects • Ketamine as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients • Ketamine as a Treatment for Post-Traumatic Stress Disorder (PTSD) • Use of Ketamine to Enhance Electroconvulsive Therapy (ECT) in Depression • A Comparison of Ketamine Infusion Versus Placebo in Opioid Tolerant and Opioid Naive Patients After Spinal Fusion • Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD) • Intranasal Ketamine in Treatment-Resistant Depression • Ketamine For Suicidal Ideation • A Study of Ketamine in Patients With Treatment-resistant Depression • Pilot Study of Ketamine in Adults With Obsessive-Compulsive Disorder (OCD) • Pharmacokinetic Alterations During ECMO • Optimization of IV Ketamine for Treatment Resistant Depression • ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD) • Effects of TS-134 on Ketamine-induced BOLD Signals in Healthy Subjects • Ketamine and Propofol Combination Versus Propofol for Upper Gastrointestinal Endoscopy • Study on the Use of Low Dose Ketamine After Gastric Bypass and Gastrectomy • Ketamine Plus Lithium in Treatment-Resistant Depression • Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD) • Research Study for Major Depressive Disorder: Investigation of Glutamate Medications • Peri-Operative Lidocane, Ketamine, or Lidocane and Ketamine Combination, Infusion for Patients Undergoing Spine Surgery • Biomarker Assessment of Glutamatergic Target Engagement • Treatment Study of Bipolar Depression • The Effect of Brief Potent Glutamatergic Modulation on Cocaine Dependence • NMDA Antagonists in Bipolar Depression • Glutamatergic Modulation of Cocaine-related Deficits • Glutamatergic Modulation of Disordered Alcohol Use • Facilitating the Behavioral Treatment of Cannabis Use Disorder • Memantine Augmentation in Treatment-Resistant Adults With Obsessive-Compulsive Disorder • The Role of Brief Potent Glutamatergic Modulation in Addressing Problem Drinking • Facilitating Rapid Naltrexone Initiation • Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence • Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders • Spinal Versus General Anesthesia With Popliteal and Adductor Canal Blocks for Ambulatory Foot and Ankle Surgery. • MRI Studies of Emotion in Depression • Evaluation of Anterior Quadratus Lumborum Block for Postoperative Analgesia in Hip Arthroscopy • Feasibility of Electro Auricular Acupuncture for Analgesia After ACL Surgery: The Feasibility of Patient Blinding and Effects on Early Postoperative Pain • Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response • Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy • Safety and Efficacy of Xyrem Oral Solution (Sodium Oxybate) Compared With Placebo in Narcoleptic Patients • Ketamine for Older Adults Pilot • Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder • A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD • Psilocybin Therapy in Advanced Cancer